| Lorlatinib Plus TNG462 in ALK+ MTAP Del NSCLC | Lorlatinib | Phase 1 | Not yet recruiting | Dana-Farber Cancer Institute | 2026-11-16 |
| Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma | Alectinib, Entrectinib | Phase 2 | Not yet recruiting | St. Jude Children's Research Hospital | 2026-11-04 |
| Ceritinib Treatment for Recurrent Meningiomas | Ceritinib | Phase 2 | Not yet recruiting | Kevin Petrecca | 2026-10-23 |
| Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors | Crizotinib | Not applicable | Active, not recruiting | National Cancer Center, Korea | 2026-10-23 |
| Perioperative Targeted Therapy in Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer With Rare Driver Mutations | Alectinib, Entrectinib | Phase 2 | Not yet recruiting | Shanghai Zhongshan Hospital | 2026-09-21 |
| TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling | Alectinib, Lorlatinib | Not applicable | Not yet recruiting | Karolinska Institutet | 2026-09-16 |
| A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Crizotinib | Phase 3 | Not yet recruiting | Guangzhou JOYO Pharma Co., Ltd | 2026-09-11 |
| Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma | Crizotinib | Phase 3 | Recruiting | IDEAYA Biosciences | 2026-09-04 |
| Molecularly Tailored Therapy in Advanced Pancreatic Cancer | Crizotinib | Phase 2 | Not yet recruiting | Herlev Hospital | 2026-09-03 |
| Study of NXP900 With Lorlatinib in ALK+ Lung Cancer | Lorlatinib | Phase 1 | Recruiting | Nuvectis Pharma, Inc. | 2026-08-25 |
| Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib | Lorlatinib | Phase 1 | Recruiting | University of Chicago | 2026-08-24 |
| A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer | Alectinib, Brigatinib | Phase 2 | Not yet recruiting | First Affiliated Hospital of Fujian Medical University | 2026-08-18 |
| Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC | Lorlatinib | Phase 2 | Not yet recruiting | Guangdong Association of Clinical Trials | 2026-08-06 |
| Management Strategy of 1L Lorlatinib With Hyperlipidemia in Stage IIIB-IV ALK Positive NSCLC | Lorlatinib | — | Not yet recruiting | Sun Yat-sen University | 2026-06-29 |
| Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed | Lorlatinib | Phase 4 | Not yet recruiting | Hunan Cancer Hospital | 2026-06-29 |
| Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC | Ensartinib, Lorlatinib | Phase 4 | Not yet recruiting | Qiming Wang | 2026-06-26 |
| OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic Therapy | Alectinib, Brigatinib | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 2026-06-18 |
| Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy | Alectinib | Phase 2 | Not yet recruiting | Wen-zhao ZHONG | 2026-05-07 |
| Treatment of Truncated ALK-positive Bone Cancer Using Crizotinib (Xalkori) or Alectinib (Alecensa) | Alectinib, Crizotinib | Phase 1 / Phase 2 | Not yet recruiting | China Medical University Hospital | 2026-05-01 |
| A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function | Crizotinib | Phase 1 | Not yet recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2026-04-20 |
| Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors. | Ensartinib | Phase 1 / Phase 2 | Recruiting | Betta Pharmaceuticals Co., Ltd. | 2026-03-04 |
| Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) | Ensartinib | Phase 1 / Phase 2 | Recruiting | Tang-Du Hospital | 2026-01-21 |
| Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC | Ensartinib | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 2025-11-19 |
| Multi Omics Molecular Characteristics and Immunophenotyping of Lung Signet Ring Cell Carcinoma | Alectinib, Crizotinib | — | Recruiting | First People's Hospital of Hangzhou | 2025-10-03 |
| Real-world Study of Taletrectinib in Advanced ROS1+ NSCLC Following Entrectinib Progression | Entrectinib | — | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 2025-09-30 |
| Study on the Mechanism of Acquired Resistance of Entrectinib | Entrectinib | — | Recruiting | Fudan University | 2025-09-30 |
| Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation | Conteltinib | Phase 1 / Phase 2 | Not yet recruiting | Shouyao Holdings (Beijing) Co. LTD | 2025-05-14 |
| Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations | Ensartinib | Phase 3 | Not yet recruiting | The First Affiliated Hospital of Guangzhou Medical University | 2025-05-02 |
| Using Tumor Models to Determine Treatments | Brigatinib, Ceritinib | Phase 2 | Recruiting | University Health Network, Toronto | 2025-02-06 |
| Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical Study | Ensartinib | Phase 4 | Not yet recruiting | Fujian Medical University Union Hospital | 2025-01-21 |
| Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD | Ensartinib | Phase 2 | Not yet recruiting | Peking University Cancer Hospital & Institute | 2025-01-17 |
| Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer | Ensartinib | Phase 2 | Not yet recruiting | West China Hospital | 2025-01-16 |
| Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC | Crizotinib, Entrectinib | — | Not yet recruiting | National Cancer Center, China | 2024-11-19 |
| Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | Entrectinib | Phase 2 | Not yet recruiting | Peking University Shenzhen Hospital | 2024-11-18 |
| Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib | Brigatinib | Phase 2 | Recruiting | Groupe Francais De Pneumo-Cancerologie | 2024-10-01 |
| Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors | Entrectinib | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 2024-07-30 |
| Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer | Entrectinib | Phase 2 | Recruiting | West China Hospital | 2024-07-01 |
| A Study of Brigatinib as Preferred First Therapy for Adults With Non-Small Cell Lung Cancer (NSCLC) ENTIRETY | Brigatinib | — | Active, not recruiting | Takeda | 2023-02-21 |
| A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) | Brigatinib | — | Active, not recruiting | Takeda | 2023-02-10 |
| Antineoplastic Drugs in Elderly Patients | Ceritinib | — | Recruiting | Shandong University | 2022-07-20 |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Brigatinib, Ceritinib | Phase 1 / Phase 2 | Recruiting | Nuvalent Inc. | 2022-05-20 |
| Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) | Brigatinib | Phase 2 | Active, not recruiting | Intergroupe Francophone de Cancerologie Thoracique | 2022-01-20 |
| Improving Public Cancer Care by Implementing Precision Medicine in Norway | Ceritinib | Phase 2 | Recruiting | Oslo University Hospital | 2021-03-26 |
| Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation | Ceritinib | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 2020-03-26 |
| Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC | Ceritinib | Phase 1 | Active, not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 2018-08-02 |
| Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study | Ceritinib | Phase 4 | Active, not recruiting | Novartis Pharmaceuticals | 2015-10-23 |